
Eurofins Scientific (ERF) | Financial Analysis & Statements
Eurofins Scientific SE | Large-cap | Healthcare
Eurofins Scientific SE | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
10.9B
Total Liabilities
5.5B
Shareholders Equity
5.4B
Debt to Equity
1.02
Cash Flow Metrics
Operating Cash Flow
33.2M
Free Cash Flow
31.6M
Revenue & Profitability Trend
Eurofins Scientific Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 7.0B | 6.5B | 6.7B | 6.7B | 5.4B |
Cost of Goods Sold | 2.2B | 2.2B | 2.2B | 2.1B | 1.7B |
Gross Profit | 4.7B | 4.4B | 4.5B | 4.6B | 3.7B |
Gross Margin % | 67.8% | 67.0% | 66.8% | 68.0% | 67.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | - | - |
Other Operating Expenses | 46.0M | 50.3M | 16.4M | 38.2M | 21.6M |
Total Operating Expenses | 46.0M | 50.3M | 16.4M | 38.2M | 21.6M |
Operating Income | 726.2M | 546.8M | 783.2M | 1.3B | 805.5M |
Operating Margin % | 10.4% | 8.4% | 11.7% | 19.0% | 14.8% |
Non-Operating Items | |||||
Interest Income | 19.3M | 11.6M | 2.2M | 2.0M | 2.7M |
Interest Expense | 150.8M | 129.4M | 105.6M | 95.0M | 103.6M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 554.6M | 423.3M | 780.0M | 1.1B | 694.4M |
Income Tax | 149.1M | 115.5M | 174.2M | 273.6M | 153.9M |
Effective Tax Rate % | 26.9% | 27.3% | 22.3% | 25.9% | 22.2% |
Net Income | 405.5M | 307.8M | 605.8M | 783.0M | 540.5M |
Net Margin % | 5.8% | 4.7% | 9.0% | 11.7% | 9.9% |
Key Metrics | |||||
EBITDA | 1.4B | 1.2B | 1.4B | 1.7B | 1.3B |
EPS (Basic) | €2.13 | €1.61 | €3.17 | €4.09 | €2.90 |
EPS (Diluted) | €2.09 | €1.57 | €3.07 | €3.90 | €2.75 |
Basic Shares Outstanding | 190600000 | 192900000 | 192500000 | 191500000 | 186200000 |
Diluted Shares Outstanding | 190600000 | 192900000 | 192500000 | 191500000 | 186200000 |
Income Statement Trend
Eurofins Scientific Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 613.9M | 1.2B | 486.6M | 515.3M | 912.4M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.1B | 1.1B | 1.1B | 1.1B | 948.5M |
Inventory | 141.9M | 139.0M | 145.6M | 154.2M | 157.0M |
Other Current Assets | -200.0K | - | -100.0K | - | - |
Total Current Assets | 2.5B | 3.1B | 2.3B | 2.3B | 2.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 86.9M | 87.0M | 950.6M | 1.9B | 1.6B |
Goodwill | 10.5B | 9.9B | 10.0B | 9.1B | 7.9B |
Intangible Assets | 787.9M | 796.0M | 919.0M | 895.7M | 825.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 8.4B | 7.8B | 7.8B | 7.0B | 6.1B |
Total Assets | 10.9B | 10.9B | 10.1B | 9.3B | 8.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 645.9M | 600.2M | 647.7M | 627.6M | 542.0M |
Short-term Debt | 478.8M | 601.0M | 213.7M | 253.9M | 237.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | -100.0K | 100.0K | - | -200.0K | - |
Total Current Liabilities | 2.1B | 2.1B | 1.8B | 1.9B | 1.7B |
Non-Current Liabilities | |||||
Long-term Debt | 3.1B | 3.3B | 3.1B | 2.5B | 2.9B |
Deferred Tax Liabilities | 109.5M | 110.0M | 133.6M | 123.6M | 115.3M |
Other Non-Current Liabilities | - | 100.0K | - | 200.0K | 300.0K |
Total Non-Current Liabilities | 3.4B | 3.6B | 3.5B | 2.8B | 3.2B |
Total Liabilities | 5.5B | 5.8B | 5.2B | 4.7B | 4.9B |
Equity | |||||
Common Stock | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M |
Retained Earnings | 2.7B | 2.4B | 2.3B | 2.0B | 1.3B |
Treasury Stock | 307.8M | 54.9M | 14.2M | 3.6M | 0 |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 5.4B | 5.1B | 4.9B | 4.7B | 3.7B |
Key Metrics | |||||
Total Debt | 3.6B | 3.9B | 3.3B | 2.8B | 3.2B |
Working Capital | 342.0M | 944.7M | 541.1M | 463.3M | 821.8M |
Balance Sheet Composition
Eurofins Scientific Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 554.6M | 423.3M | 780.0M | 1.1B | 694.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 138.3M | 137.7M | 136.1M | 131.0M | 124.5M |
Working Capital Changes | 47.0M | -11.1M | 61.4M | -96.7M | -144.6M |
Operating Cash Flow | 855.6M | 655.9M | 1.1B | 1.3B | 778.4M |
Investing Activities | |||||
Capital Expenditures | -443.4M | -471.7M | -561.2M | -419.6M | -305.6M |
Acquisitions | -344.3M | -150.8M | -214.7M | -532.6M | -177.2M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -787.8M | -622.6M | -775.8M | -952.3M | -482.8M |
Financing Activities | |||||
Share Repurchases | -271.9M | -55.8M | -15.8M | -3.6M | 0 |
Dividends Paid | -95.6M | -191.9M | -192.1M | -130.4M | -500.0K |
Debt Issuance | 118.0M | 638.5M | 633.9M | 826.3M | 946.2M |
Debt Repayment | -477.7M | -90.0M | -82.9M | -1.3B | -1.3B |
Financing Cash Flow | -780.5M | 677.5M | -95.4M | -588.1M | 169.8M |
Free Cash Flow | 790.5M | 467.8M | 476.1M | 1.0B | 868.0M |
Net Change in Cash | -712.7M | 710.8M | 227.4M | -257.9M | 465.4M |
Cash Flow Trend
Eurofins Scientific Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
30.01
Forward P/E
19.63
Price to Book
3.53
Price to Sales
1.71
Profitability Ratios
Profit Margin
6.05%
Operating Margin
13.16%
Return on Equity
8.68%
Return on Assets
5.46%
Financial Health
Current Ratio
1.26
Debt to Equity
88.06
Beta
0.77
Per Share Data
EPS (TTM)
€2.27
Book Value per Share
€19.28
Revenue per Share
€38.59
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
erf | 12.2B | 30.01 | 3.53 | 8.68% | 6.05% | 88.06 |
bioMérieux S.A | 15.0B | 35.00 | 3.57 | 10.68% | 10.86% | 11.65 |
Lumibird S.A | 400.6M | 70.00 | 2.02 | 2.91% | 2.71% | 81.34 |
Eurofins Cerep SAS | 92.8M | 12.97 | - | 10.49% | 17.67% | 0.46 |
Klea Holding | 64.5M | 17.87 | 2.27 | 5.35% | 8.14% | 21.13 |
Predilife S.A | 12.3M | - | - | -4,653.75% | 97.76% | -1.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.